Mereo BioPharma Group plc
MREO$368M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON36 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
MREO News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
BCT197
Pulmonary Disease, Chronic Obstructive
Prednisone
Chronic Obstructive Pulmonary Disease
Alvelestat oral tablet - dose 1
Alpha 1-Antitrypsin Deficiency
Etigilimab
Solid Tumor, Adult
BGS649
Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649
Endometriosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Prednisone | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Etigilimab | Phase 2 | Solid Tumor, Adult | - | - |
BGS649 | Phase 2 | Hypogonadotropic Hypogonadism | - | - |
Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply